Evaluation of Regret in Kidney Transplantation
DONOR
Decisional Regret in a Prospective Cohort of Renal Transplant Recipients: the DONOR Study
2 other identifiers
observational
250
1 country
1
Brief Summary
Decisional regret is a negative feeling, involving distress or remorse following a decision. This has been studied in several areas such as psychology, economy or marketing. Patients suffering from end-stage renal disease may choose between dialysis and transplantation. This decision-making process is shared with the nephrologist, who explained to the patient the pros and cons of these two possibilities. Although transplantation offers a better life expectancy and quality of life than dialysis, nothing is known about the proportion of patients regretting their choice to be transplanted. The DONOR study aims to determine the proportion of patients regretting their decision, in a prospective cohort of renal transplant recipients. The decisional regret will be assessed by the DRS ("Decisional Regret Scale"), associated with the RetransQoL, a quality of life questionnaire.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2022
CompletedFirst Submitted
Initial submission to the registry
February 17, 2022
CompletedFirst Posted
Study publicly available on registry
March 16, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2025
CompletedNovember 29, 2023
November 1, 2023
3.4 years
February 17, 2022
November 28, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Decisional regret at 12 months post kidney transplantation, defined as a score ≥30 on the Decisional Regret Scale
The decisional regret scale consists of five items addressing the notion of regret from different perspectives. The patient is asked to respond to each item using a 5-point Likert-type scale. The results of the Decisional Regret Scale are converted into a score from 0 to 100, with values increasing in multiples of 5. A score of 0 means no regret. Three categories of the DRE score were created: no regret (score = 0), low regret (score between 5 and 25), and moderate to high regret (score ≥ 30
At 12 months post-transplantation
Secondary Outcomes (3)
Specific Quality of Life Scale (ReTransQoL)
At 1, 3, 6 and 12 months post-transplantation
Variation of decisional regret over time, following kidney transplantation, using the Decisional Regret Scale
At 1, 3, 6 and 12 months post-transplantation
Identification of biological, psychological and sociological risk factors for decisional regret at 12 months post kidney transplantation, defined as a score ≥30 on the Decisional Regret Scale
At baseline, and during the 12 months follow-up period.
Study Arms (1)
Cohort of renal transplant recipients
Interventions
The DRS is a self-administered questionnaire including 5 items assessing decisional regret in a score graduated between 0 and 100 (0 = no regret).This scale is associated with the ReTransQoL, a specific quality of life questionnaire. Questionnaires are administrated at 1, 3, 6 and 12 months post-transplantation.
Eligibility Criteria
Patients who received a kidney transplant in the nephrology department of the Lille University Hospital
You may qualify if:
- Kidney transplantation in the Lille University Hospital
- Functional kidney graft after 28 days post transplantation
You may not qualify if:
- Previous other solid organ transplant
- Combined transplantation (kidney and liver for example)
- Cognitive disorders
- Lack of French language skill
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU Lille
Lille, 59000, France
Study Officials
- PRINCIPAL INVESTIGATOR
Mehdi Maanaoui, MD
University Hospital, Lille
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 17, 2022
First Posted
March 16, 2022
Study Start
February 1, 2022
Primary Completion
July 1, 2025
Study Completion
July 1, 2025
Last Updated
November 29, 2023
Record last verified: 2023-11